Pregnancy and Substance Use

Substance use during pregnancy involves two patients at once: the pregnant person and the developing fetus. Exposures cross the placenta and can affect pregnancy outcomes, fetal development, and the newborn, while the perinatal period also creates distinctive opportunities and barriers for engaging people in care.

Definition

Pregnancy and substance use denotes the use of alcohol, tobacco, opioids, or other substances during gestation, together with the resulting effects on pregnancy, the fetus, and the neonate, and the framework of care addressing them.

Scope

This topic covers the principal substances of concern in pregnancy, the concept of prenatal exposure and its consequences, neonatal abstinence syndrome (neonatal opioid withdrawal), and the population-specific considerations that shape perinatal addiction care. It is a reference entry on the clinical and developmental significance of perinatal substance use, not clinical guidance.

Core questions

• How do substances reach and affect the developing fetus?
• What is neonatal abstinence syndrome and why does it occur?
• How does substance use in pregnancy affect pregnancy and birth outcomes?
• Why is the perinatal period both a high-risk and high-opportunity window for engaging care?

Key concepts

• Placental transfer of substances
• Prenatal (in utero) exposure
• Neonatal abstinence syndrome
• Neonatal opioid withdrawal syndrome
• Teratogenic and developmental effects
• Perinatal engagement in care
• Two-patient model

Mechanisms

Many psychoactive substances cross the placenta and reach the fetal circulation. Chronic fetal exposure to opioids can lead, after birth, to neonatal abstinence syndrome, a withdrawal state in the newborn marked by neurologic, gastrointestinal, and autonomic signs (McQueen, 2016). Other substances act through teratogenic or neurodevelopmental pathways during sensitive windows of gestation. Because the maternal and fetal compartments are pharmacologically linked, decisions in the perinatal period weigh effects on both (Klaman, 2017).

Clinical relevance

Understanding perinatal substance use is part of how addiction medicine and obstetric care intersect, and it informs how clinicians appraise risk for the pregnant patient and the newborn. This entry describes the clinical significance of these exposures; it does not provide dosing or individualised management direction, which belong to current obstetric and addiction guidelines.

Epidemiology

Neonatal abstinence syndrome rose substantially in the United States during the 2000s alongside increasing opioid use, with associated increases in hospital costs and length of stay (Patrick, 2012). Perinatal substance use spans alcohol, tobacco, opioids, and stimulants, and prevalence varies by substance and setting (Klaman, 2017).

Evidence & guidelines

Evidence in this topic ranges from large administrative cohorts documenting trends in neonatal abstinence syndrome (Patrick, 2012) to literature reviews synthesising care for pregnant and parenting people with opioid use disorder (Klaman, 2017). National guidance exists for perinatal opioid use disorder; specific recommendations belong to those sources rather than to this reference entry.

History

Concern about prenatal substance exposure grew through the twentieth century, from recognition of fetal alcohol effects to, more recently, the marked rise in neonatal abstinence syndrome accompanying the opioid epidemic. Patrick and colleagues (2012) quantified this rise in national data, and subsequent reviews consolidated guidance for perinatal opioid use disorder (Klaman, 2017).

Debates

How should newborns exposed to opioids in utero be assessed and supported?

Approaches to identifying and supporting infants with neonatal abstinence syndrome have evolved, with ongoing discussion about assessment tools and non-pharmacologic versus pharmacologic support; specifics belong to clinical guidance.

How should care for pregnant people with opioid use disorder be organised?

Reviews emphasise integrated, non-punitive, evidence-informed perinatal care, but service models and policy approaches differ across settings.

Key figures

• Stephen Patrick
• Hendrée Jones
• Karen McQueen

Seminal works

• patrick-2012
• mcqueen-2016
• klaman-2017

Frequently asked questions

What is neonatal abstinence syndrome?

It is a withdrawal state in a newborn who was exposed to opioids (or certain other substances) in utero, producing neurologic, gastrointestinal, and autonomic signs after birth.

Why is pregnancy considered a special context for substance use?

Because substances can cross the placenta and affect the fetus and newborn, and because the perinatal period changes both the risks involved and the opportunities to engage a patient in care.